Contrast-enhanced mammography versus conventional imaging in women recalled from breast cancer screening (RACER trial): a multicentre, open-label, randomised controlled clinical trial

被引:4
|
作者
Neeter, Lidewij M. F. H. [1 ,2 ]
Nelemans, Patricia J. [3 ]
Raat , H. P. J. [4 ]
Frotscher, Caroline [5 ]
Duvivier, Katya M. [6 ]
Essers, Brigitte A. B. [7 ,8 ]
Smidt, Marjolein L. [2 ,9 ]
Wildberger, Joachim E. [1 ]
Lobbes, Marc B. I. [1 ,2 ,5 ]
机构
[1] Maastricht Univ, Med Ctr, Dept Radiol & Nucl Med, POB 5800, NL-6202 AZ Maastricht, Netherlands
[2] Maastricht Univ, GROW Sch Oncol & Reprod, POB 616, NL-6200 MD Maastricht, Netherlands
[3] Maastricht Univ, Dept Epidemiol, POB 616, NL-6200 MD Maastricht, Netherlands
[4] Laurentius Hosp, Dept Radiol, POB 920, NL-6040 AX Roermond, Netherlands
[5] Zuyderland Med Ctr, Dept Med Imaging, POB 5500, NL-6130 MB Geleen, Netherlands
[6] Amsterdam Univ Med Ctr, Dept Radiol, POB 7057, NL-1007 MB Amsterdam, Netherlands
[7] Maastricht Univ, Med Ctr, Dept Clin Epidemiol & Med Technol Assessment, POB 5800, NL-6200 MD Maastricht, Netherlands
[8] Maastricht Univ, CAPHRI Care & Publ Hlth Res Inst, POB 616, NL-6200 MD Maastricht, Netherlands
[9] Maastricht Univ, Med Ctr, Dept Surg, POB 5800, NL-6202 AZ Maastricht, Netherlands
来源
LANCET REGIONAL HEALTH-EUROPE | 2024年 / 44卷
关键词
Breast neoplasm; Mammography; Screening; SPECTRAL MAMMOGRAPHY; DIAGNOSTIC PERFORMANCE;
D O I
10.1016/j.lanepe.2024.100987
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Women recalled from breast cancer screening receive post-screening work-up in the hospital with conventional breast imaging. The RACER trial aimed to study whether contrast-enhanced mammography (CEM) as primary imaging instead of conventional imaging resulted in more accurate and efficient diagnostic work-up in recalled women. Methods In this randomised, controlled trial (registered under NL6413/NTR6589) participants were allocated using deterministic minimisation to CEM or conventional imaging as a primary work-up tool in two general and two academic hospitals. Predefined patients 'factors were reason for recall, BI-RADS score, and study centre. Primary outcomes were sensitivity and specifi city. Secondary outcomes were the proportion of women needing supplemental examinations, and number of days until diagnosis. Findings Between April, 2018, and September, 2021, 529 patients recalled from the Dutch screening program were randomised, 265 to conventional imaging and 264 to CEM. Three patients in the control arm had to be excluded from analysis due to a protocol breach. After the entire work-up, sensitivity was 98.0% (95% CI; 92.2 - 99.7%) in the intervention arm and 97.7% (91.8 - 99.6%) in the control arm (p = 1.0), and speci fi city was 75.6% (72.5 - 76.6%) and 75.4% (72.5 - 76.4%, p = 1.0), respectively. Based on only primary full- field digital mammography/digital breast tomosynthesis or CEM, final diagnosis was reached in 27.7% (73/264) in the intervention arm and 1.1% (3/262) in the control arm. The frequency of supplemental imaging was signi fi cantly higher in the control arm (p < 0.0001). Median time needed to reach fi nal diagnosis was comparable: 1 day (control arm: IQR 0 - 4; intervention arm: IQR 0 - 3). Thirteen malignant occult lesions were detected using CEM, versus three using conventional imaging. No serious adverse events occurred. Interpretation Diagnostic accuracy of CEM in the work-up of recalled women is comparable with conventional imaging. However, work-up with CEM as primary imaging is a more efficient pathway. Copyright (c) 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).
引用
收藏
页数:11
相关论文
共 7 条
  • [1] Rapid Access to Contrast-Enhanced spectral mammogRaphy in women recalled from breast cancer screening: the RACER trial study design
    Neeter, L. M. F. H.
    Houben, I. P. L.
    Nelemans, P. J.
    Van Nijnatten, T. J. A.
    Pijnappel, R. M.
    Frotscher, C.
    Osinga-de Jong, M.
    Sanders, F.
    Van Dalen, T.
    Raat, H. P. J.
    Essers, B. A. B.
    Wildberger, J. E.
    Smidt, M. L.
    Lobbes, M. B., I
    TRIALS, 2019, 20 (01)
  • [2] Rapid Access to Contrast-Enhanced spectral mammogRaphy in women recalled from breast cancer screening: the RACER trial study design
    L. M. F. H. Neeter
    I. P. L. Houben
    P. J. Nelemans
    T. J. A. Van Nijnatten
    R. M. Pijnappel
    C. Frotscher
    M. Osinga-de Jong
    F. Sanders
    T. Van Dalen
    H. P. J. Raat
    B. A. B. Essers
    J. E. Wildberger
    M. L. Smidt
    M. B. I. Lobbes
    Trials, 20
  • [3] Contrast-enhanced mammography (CEM) versus MRI for breast cancer staging: detection of additional malignant lesions not seen on conventional imaging
    Taylor, Donna B.
    Burrows, Sally
    Saunders, Christobel M.
    Parizel, Paul M.
    Ives, Angela
    EUROPEAN RADIOLOGY EXPERIMENTAL, 2023, 7 (01)
  • [4] Multicentre randomised controlled trial examining the cost-effectiveness of contrast-enhanced high field magnetic resonance imaging in women with primary breast cancer scheduled for wide local excision (COMICE)
    Turnbull, L. W.
    Brown, S. R.
    Olivier, C.
    Harvey, I.
    Brown, J.
    Drew, P.
    Hanby, A.
    Manca, A.
    Napp, V.
    Sculpher, M.
    Walker, L. G.
    Walker, S.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 (01) : 1 - +
  • [5] Contrast-enhanced mammography (CEM) versus MRI for breast cancer staging: detection of additional malignant lesions not seen on conventional imaging
    Donna B. Taylor
    Sally Burrows
    Christobel M. Saunders
    Paul M. Parizel
    Angela Ives
    European Radiology Experimental, 7
  • [6] A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women
    Maxwell, Anthony J.
    Michell, Michael
    Lim, Yit Y.
    Astley, Susan M.
    Wilson, Mary
    Hurley, Emma
    Evans, D. Gareth
    Howell, Anthony
    Iqbal, Asif
    Kotre, John
    Duffy, Stephen
    Morris, Julie
    EUROPEAN JOURNAL OF RADIOLOGY, 2017, 94 : 133 - 139
  • [7] Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
    Lee, Soohyeon
    Im, Seock-Ah
    Kim, Gun Min
    Jung, Kyung Hae
    Kang, Seok Yun
    Park, In Hae
    Kim, Jee Hyun
    Lee, Kyoung Eun
    Ahn, Hee Kyung
    Lee, Moon Hee
    Kim, Hee-Jun
    Kim, Han Jo
    Lee, Jong In
    Koh, Su-Jin
    Park, Yeon Hee
    CANCERS, 2020, 12 (11) : 1 - 12